PMID- 2846314
OWN - NLM
STAT- MEDLINE
DCOM- 19881205
LR  - 20190908
IS  - 0277-5379 (Print)
IS  - 0277-5379 (Linking)
VI  - 24
IP  - 9
DP  - 1988 Sep
TI  - Oral etoposide preceding cisplatin in advanced non small cell lung cancer 
      (NSCLC). A phase II study.
PG  - 1515-20
AB  - Forty male patients with locally advanced (LD; 11 patients) and extensive (ED; 29 
      patients) NSCLC were treated with oral etoposide (240 mg/m2 days 1-3) preceding 
      intravenous cisplatin (100 mg/m2 day 4) at 4 weekly intervals. Eleven patients 
      achieved major response (27.5%; 1 CR, 10 PR). Minor response (MR) occurred in 
      seven patients (17.5%); stable disease (SD) in seven patients (17.5%) and 
      progressive disease (PD) in 15 (37.5%). The median duration of response in major 
      responders was 31 weeks. The median survival time (MST) in all patients was 42 
      weeks. Patients achieving response, and stable disease lived significantly longer 
      than progressors (P less than 0.0001; 56 vs. 9 weeks respectively). The MST of 
      non-progressors in both LD and ED was significantly increased as compared to 
      progressors. Two patients with poor risk prognostic variables died from 
      myelosuppression-related infection early during the first course of chemotherapy. 
      The remainder of the courses were without severe hematological complications. 
      Alopecia was the most common side-effect. Gastro-intestinal, neurological and 
      renal complications were mild to moderate. Intravenous etoposide can be replaced 
      by the oral formulation with preservation of antitumoral activity in NSCLC 
      patients, offering the advantage of maximal treatment outside the hospital.
FAU - Focan, C
AU  - Focan C
AD  - Clinique Ste-Elisabeth, Department of Medical Oncology, University of Liege, 
      Belgium.
FAU - Vandermoten, G
AU  - Vandermoten G
FAU - Boossy, J
AU  - Boossy J
FAU - Schallier, D
AU  - Schallier D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Cancer Clin Oncol
JT  - European journal of cancer & clinical oncology
JID - 8112045
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alopecia/chemically induced
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Drug Evaluation
MH  - Etoposide/administration & dosage/adverse effects
MH  - Humans
MH  - Leukopenia/chemically induced
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Prognosis
EDAT- 1988/09/01 00:00
MHDA- 1988/09/01 00:01
CRDT- 1988/09/01 00:00
PHST- 1988/09/01 00:00 [pubmed]
PHST- 1988/09/01 00:01 [medline]
PHST- 1988/09/01 00:00 [entrez]
AID - 10.1016/0277-5379(88)90344-6 [doi]
PST - ppublish
SO  - Eur J Cancer Clin Oncol. 1988 Sep;24(9):1515-20. doi: 
      10.1016/0277-5379(88)90344-6.